DK3400293T3 - Modificeret onkolytisk virus - Google Patents

Modificeret onkolytisk virus Download PDF

Info

Publication number
DK3400293T3
DK3400293T3 DK17701910.6T DK17701910T DK3400293T3 DK 3400293 T3 DK3400293 T3 DK 3400293T3 DK 17701910 T DK17701910 T DK 17701910T DK 3400293 T3 DK3400293 T3 DK 3400293T3
Authority
DK
Denmark
Prior art keywords
oncolytic virus
modified oncolytic
modified
virus
oncolytic
Prior art date
Application number
DK17701910.6T
Other languages
English (en)
Other versions
DK3400293T4 (da
Inventor
Robert Coffin
Original Assignee
Replimune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57796748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3400293(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1600382.4A external-priority patent/GB201600382D0/en
Priority claimed from GBGB1600381.6A external-priority patent/GB201600381D0/en
Priority claimed from GBGB1600380.8A external-priority patent/GB201600380D0/en
Application filed by Replimune Ltd filed Critical Replimune Ltd
Publication of DK3400293T3 publication Critical patent/DK3400293T3/da
Application granted granted Critical
Publication of DK3400293T4 publication Critical patent/DK3400293T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK17701910.6T 2016-01-08 2017-01-09 Modificeret onkolytisk virus DK3400293T4 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1600382.4A GB201600382D0 (en) 2016-01-08 2016-01-08 Engineered virus
GBGB1600381.6A GB201600381D0 (en) 2016-01-08 2016-01-08 Virus strain
GBGB1600380.8A GB201600380D0 (en) 2016-01-08 2016-01-08 Modified virus
PCT/GB2017/050036 WO2017118864A1 (en) 2016-01-08 2017-01-09 Modified oncolytic viurs

Publications (2)

Publication Number Publication Date
DK3400293T3 true DK3400293T3 (da) 2020-10-19
DK3400293T4 DK3400293T4 (da) 2023-08-28

Family

ID=57796748

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17701910.6T DK3400293T4 (da) 2016-01-08 2017-01-09 Modificeret onkolytisk virus
DK17700385.2T DK3400291T4 (da) 2016-01-08 2017-01-09 Manipuleret virus
DK17700384.5T DK3400290T5 (da) 2016-01-08 2017-01-09 Onkolytisk virusstamme

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK17700385.2T DK3400291T4 (da) 2016-01-08 2017-01-09 Manipuleret virus
DK17700384.5T DK3400290T5 (da) 2016-01-08 2017-01-09 Onkolytisk virusstamme

Country Status (15)

Country Link
US (12) US10570377B2 (da)
EP (7) EP3778881A1 (da)
JP (6) JP7038065B2 (da)
KR (1) KR20180103956A (da)
CN (3) CN109415703B (da)
AU (2) AU2017205216B2 (da)
BR (1) BR112018013930A2 (da)
CA (3) CA3010987A1 (da)
DK (3) DK3400293T4 (da)
ES (3) ES2841300T5 (da)
HK (3) HK1257224A1 (da)
IL (2) IL260480B (da)
MX (1) MX2018008413A (da)
SG (2) SG10202108724YA (da)
WO (4) WO2017118865A1 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2695101A (en) * 2000-01-21 2001-07-31 Biovex Ltd Virus strains
HUE037460T2 (hu) 2005-12-02 2018-08-28 Icahn School Med Mount Sinai Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk
WO2008153832A2 (en) 2007-05-31 2008-12-18 Krishnan Ramu Switched reluctance machines with minimum stator core
NZ711946A (en) 2013-03-14 2020-05-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
RU2711380C2 (ru) 2015-07-16 2020-01-16 Байоксэл Терапьютикс, Инк. Новый подход к лечению рака с применением иммуномодуляции
JP7038065B2 (ja) * 2016-01-08 2022-03-17 レプリミュン リミテッド 腫瘍溶解性ウイルス株
EP4089166A1 (en) 2016-01-27 2022-11-16 Oncorus, Inc. Oncolytic viral vectors and uses thereof
JP6802275B2 (ja) * 2016-04-22 2020-12-16 イムヴィラ・カンパニー・リミテッドＩｍｍｖｉｒａ Ｃｏ．， Ｌｉｍｉｔｅｄ 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス（ｏＨＳＶ）偏性ベクター及びその構築体の構築
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
BR112020001559A2 (pt) 2017-07-26 2020-08-11 Oncorus, Inc. vetores virais oncolíticos e usos dos mesmos
UY37829A (es) 2017-08-03 2019-01-31 Amgen Inc Muteínas de interleucina 21 y métodos de tratamiento
EP4403175A3 (en) 2017-09-08 2024-10-02 Amgen Inc. Inhibitors of kras g12c and methods of using the same
CN109554353B (zh) * 2017-09-26 2021-08-06 杭州康万达医药科技有限公司 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
AU2018364752A1 (en) * 2017-11-13 2020-05-28 Bioxcel Therapeutics, Inc. Methods and compositions for treating cancer by modifying multiple arms of the immune system
WO2019133847A1 (en) * 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
ES2941740T3 (es) 2018-01-12 2023-05-25 Amgen Inc Anticuerpos anti-PD-1 y métodos de tratamiento
EP3743095A1 (en) * 2018-01-26 2020-12-02 Celldex Therapeutics, Inc. Methods of treating cancer with dendritic cell mobilizing agents
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
CN108635380A (zh) * 2018-04-13 2018-10-12 北京唯源立康生物科技有限公司 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用
WO2019243847A1 (en) * 2018-06-21 2019-12-26 Replimune Limited Treatment using oncolytic virus
CA3103374A1 (en) * 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery
CN109161561A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法
US20220133823A1 (en) * 2018-09-10 2022-05-05 Genesail Biotech (Shanghai) Co. Ltd. A modified oncolytic virus, composition and use thereof
AU2019351255A1 (en) 2018-09-26 2021-04-29 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
AR117547A1 (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas
CN111606999B (zh) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用
EP3935182A1 (en) 2019-03-05 2022-01-12 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
CN110054678B (zh) * 2019-05-16 2023-04-18 中国医学科学院血液病医院（血液学研究所） 一种膜结合型mFLT3LG蛋白及其应用
CN110218707B (zh) * 2019-05-29 2021-10-22 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
KR20220044310A (ko) * 2019-08-05 2022-04-07 고쿠리츠 다이가쿠 호우징 도우카이 고쿠리츠 다이가쿠 기코우 악성 종양을 치료하기 위한 병용약, 악성 종양을 치료하기 위한 의약 조성물 및 악성 종양 치료용 의약 조성물
WO2021092427A1 (en) * 2019-11-06 2021-05-14 Memgen, Inc. Replication-enhanced oncolytic adenoviruses
CN110982795B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种单纯疱疹病毒及其用途
CN110982794B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种修饰的单纯疱疹病毒
WO2021175293A1 (zh) * 2020-03-05 2021-09-10 北京唯源立康生物科技有限公司 一种单纯疱疹病毒及其用途
WO2021193081A1 (ja) * 2020-03-23 2021-09-30 国立大学法人東海国立大学機構 １型単純ヘルペスウイルス
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CN112941039A (zh) * 2021-02-01 2021-06-11 南京大学 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用
DE102022104146A1 (de) 2021-03-19 2022-09-22 Yamada Manufacturing Co., Ltd. Lenkvorrichtung
US20240245739A1 (en) * 2021-05-18 2024-07-25 The Penn State Research Foundation Oncolytic virus based cancer therapy
CN113583979B (zh) * 2021-08-03 2022-11-22 杭州荣谷生物科技有限公司 一种重组溶瘤痘苗病毒、制备方法及其用途
WO2023136212A1 (ja) 2022-01-11 2023-07-20 三菱マテリアル株式会社 表面被覆切削工具
WO2024055022A2 (en) * 2022-09-08 2024-03-14 Virogin Biotech Canada Ltd Oncolytic virus expressing an immune cell engager for tumor targeting

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
WO1993019591A1 (en) 1992-03-31 1993-10-14 Arch Development Corporation Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
CA2234060A1 (en) 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
EP1955703A1 (en) 1999-11-12 2008-08-13 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
AU2695101A (en) 2000-01-21 2001-07-31 Biovex Ltd Virus strains
CA2441663C (en) 2001-03-27 2013-01-22 Medigene, Inc. Viral vectors and their use in therapeutic methods
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
RU2007114111A (ru) 2004-11-04 2008-12-10 Пфайзер Продактс Инк. (Us) Лечение рака молочной железы с помощью комбинации антитела против ctla4 и ингибитора ароматазы
US9866961B2 (en) 2004-12-01 2018-01-09 Todd Beauchamp Multi-channel loudspeaker enclosure with laterally projecting wings and method for orienting and driving multiple loudspeakers
AR053026A1 (es) 2005-03-08 2007-04-18 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
PT1877090E (pt) 2005-05-06 2014-04-15 Providence Health System Proteína de fusão trimérica de imunoglobulina-ox40 e métodos de utilização
CN101495126B (zh) 2005-06-23 2016-01-06 休斯顿大学 Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
EP2307033A4 (en) 2008-05-29 2012-06-13 Gen Hospital Corp USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
KR101361416B1 (ko) 2008-10-08 2014-02-21 인트렉손 코포레이션 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
AU2010321773A1 (en) 2009-11-20 2012-06-14 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
US20130202639A1 (en) * 2010-03-25 2013-08-08 Konstantin G. Kousoulas Synthetic Herpes Simplex Viruses for Treatment of Cancers
WO2011118866A1 (ko) 2010-03-26 2011-09-29 연세대학교 산학협력단 네트워크를 통한 심사요청 방법
WO2012038606A1 (en) * 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
PL2753355T3 (pl) * 2011-09-08 2019-04-30 Benevir Biopharm Inc Onkolityczny wirus opryszczki pospolitej i jego zastosowania lecznicze
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
AU2013211871B2 (en) 2012-01-25 2017-12-14 Board Of Regents, The University Of Texas System Biomarkers and combination therapies using oncolytic virus and immunomodulation
WO2014022138A2 (en) 2012-07-30 2014-02-06 Alex Wah Hin Yeung Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator
PT3381942T (pt) 2012-08-30 2021-05-24 Amgen Inc Método para o tratamento do melanoma que utiliza um vírus herpes simplex e um inibidor de checkpoint imunitário
WO2014066532A1 (en) 2012-10-23 2014-05-01 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
BR112015018418A2 (pt) 2013-02-22 2017-07-18 Hoffmann La Roche métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
NZ711946A (en) 2013-03-14 2020-05-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
US10519426B2 (en) 2013-09-03 2019-12-31 Medimmune Limited Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia
PL3021859T3 (pl) 2013-10-25 2018-06-29 Psioxus Therapeutics Limited Adenowirusy onkolityczne wyposażone w geny heterolityczne
AU2014342465B2 (en) 2013-10-28 2018-03-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic HSV vector
US20160289645A1 (en) 2013-11-22 2016-10-06 Dnatrix, Inc. Adenovirus Expressing Immune Cell Stimulatory Receptor Agonist(s)
US10933106B2 (en) 2014-02-25 2021-03-02 Deutsches Krebsforschungszentrum RNA viruses for immunovirotherapy
MA39818A (fr) * 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
CA2955084C (en) 2014-07-16 2023-08-29 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
EP3552615B8 (en) † 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
US20160040186A1 (en) 2014-08-07 2016-02-11 Xiaoyun Liu Dna construct and method for transgene expression
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
EP3247672B1 (en) 2015-01-23 2018-11-28 Dreamwell, Ltd. Automated mattress manufacturing process and apparatus
JP7038065B2 (ja) * 2016-01-08 2022-03-17 レプリミュン リミテッド 腫瘍溶解性ウイルス株
JP6802275B2 (ja) 2016-04-22 2020-12-16 イムヴィラ・カンパニー・リミテッドＩｍｍｖｉｒａ Ｃｏ．， Ｌｉｍｉｔｅｄ 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス（ｏＨＳＶ）偏性ベクター及びその構築体の構築
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
WO2019243847A1 (en) 2018-06-21 2019-12-26 Replimune Limited Treatment using oncolytic virus

Also Published As

Publication number Publication date
US20190022157A1 (en) 2019-01-24
AU2017205216A1 (en) 2018-08-09
JP2019500909A (ja) 2019-01-17
KR20180103956A (ko) 2018-09-19
US12024724B2 (en) 2024-07-02
US10612005B2 (en) 2020-04-07
SG11201805835WA (en) 2018-08-30
US20200199542A1 (en) 2020-06-25
CA3011009A1 (en) 2017-07-13
CA3011004A1 (en) 2017-07-13
US12049647B2 (en) 2024-07-30
US20230212531A1 (en) 2023-07-06
ES2943150T3 (es) 2023-06-09
HK1257074A1 (zh) 2019-10-11
HK1257480A1 (zh) 2019-10-18
EP3400293A1 (en) 2018-11-14
CN109153977B (zh) 2022-11-01
US11473063B2 (en) 2022-10-18
ES2841300T3 (es) 2021-07-08
CN109153977A (zh) 2019-01-04
DK3400290T5 (da) 2024-09-23
JP7038664B2 (ja) 2022-03-18
EP4219696A3 (en) 2023-09-27
EP3805376A1 (en) 2021-04-14
WO2017118866A1 (en) 2017-07-13
JP7038065B2 (ja) 2022-03-17
AU2017205216B2 (en) 2022-11-24
ES2831080T5 (es) 2023-10-30
US10626377B2 (en) 2020-04-21
JP2019501670A (ja) 2019-01-24
JP2019501671A (ja) 2019-01-24
US11427810B2 (en) 2022-08-30
US20230130992A1 (en) 2023-04-27
US10570377B2 (en) 2020-02-25
WO2017118864A1 (en) 2017-07-13
JP2022078225A (ja) 2022-05-24
EP3400292A1 (en) 2018-11-14
DK3400291T4 (da) 2024-04-02
EP3400291B2 (en) 2024-02-28
US20210254019A1 (en) 2021-08-19
ES2841300T5 (es) 2024-08-06
WO2017118865A1 (en) 2017-07-13
ES2831080T3 (es) 2021-06-07
DK3400293T4 (da) 2023-08-28
EP3400292B1 (en) 2020-08-26
AU2022279486A1 (en) 2023-02-02
SG10202108724YA (en) 2021-09-29
US10947513B2 (en) 2021-03-16
HK1257224A1 (zh) 2019-10-18
IL282985B (en) 2022-04-01
WO2017118867A1 (en) 2017-07-13
CN109415703A (zh) 2019-03-01
DK3400291T3 (da) 2020-11-30
US20240018488A1 (en) 2024-01-18
CN109312309B (zh) 2024-04-02
IL282985A (en) 2021-06-30
EP4219696A2 (en) 2023-08-02
US20190032024A1 (en) 2019-01-31
US20240301365A1 (en) 2024-09-12
EP3400290B1 (en) 2023-04-05
JP7295192B2 (ja) 2023-06-20
CA3010987A1 (en) 2017-07-13
EP3400293B2 (en) 2023-07-12
US20230203453A1 (en) 2023-06-29
US20200208122A1 (en) 2020-07-02
CN109312309A (zh) 2019-02-05
JP6959258B2 (ja) 2021-11-02
US20190015466A1 (en) 2019-01-17
BR112018013930A2 (pt) 2018-12-11
CN109415703B (zh) 2024-08-30
EP3400290A1 (en) 2018-11-14
MX2018008413A (es) 2019-02-20
EP3400293B1 (en) 2020-09-16
EP3400291A1 (en) 2018-11-14
IL260480B (en) 2021-05-31
JP2023113885A (ja) 2023-08-16
EP3400291B1 (en) 2020-11-04
US20190040366A1 (en) 2019-02-07
DK3400290T3 (da) 2023-05-01
EP3778881A1 (en) 2021-02-17
JP2022002531A (ja) 2022-01-11

Similar Documents

Publication Publication Date Title
DK3400293T3 (da) Modificeret onkolytisk virus
DK3405050T3 (da) Børnesikret snusbeholder
DK3393510T3 (da) Zikavirusvaccine
DK3172319T3 (da) Coronavirus
DK3108000T3 (da) Adeno-associeret virusvektor
EP3659614C0 (en) ONCOLYTIC VACCINIA VIRUS
DK3436823T3 (da) Antigen-array
DK3335532T3 (da) Tandharve
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
DK3130392T3 (da) Virusfjernelsesmembran
DK3402792T3 (da) Quinolin-2-on-derivater
MA45305A (fr) Suspension améliorée
DE112017006386A5 (de) Schraubarbeitszylinder
DK3263590T3 (da) Fiskevirus
DE112017000734A5 (de) Glycolsensor
CL2016001249S1 (es) Conjunto soplador
FI20165334A (fi) Kirves
DK3129037T3 (da) Onkolytiske koppevirusvektorer
DK3323708T3 (da) Bovfender
DE112017005767A5 (de) Nasslaufende lamellenkupplung
DK3371324T3 (da) Virusbiomarkører og anvendelser deraf
DK3430609T3 (da) Smartflag
DK3295800T3 (da) Sandwichkiksindretning
DE112017006474A5 (de) Gargerätevorrichtung
DE112017000296A5 (de) Radgeschwindigkeitssensorvorrichtung